Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) saw a significant increase in short interest in the month of February. As of February 27th, there was short interest totaling 1,097 shares, an increase of 79.8% from the February 12th total of 610 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 1,575 shares, the short-interest ratio is currently 0.7 days. Based on an average daily volume of 1,575 shares, the short-interest ratio is currently 0.7 days. Approximately 0.7% of the company’s shares are short sold.

Hedge Funds Weigh In On Amplify Weight Loss Drug & Treatment ETF

A hedge fund recently bought a new stake in Amplify Weight Loss Drug & Treatment ETF stock. Cravens & Co Advisors LLC purchased a new position in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,023 shares of the company’s stock, valued at approximately $390,000. Cravens & Co Advisors LLC owned 10.02% of Amplify Weight Loss Drug & Treatment ETF as of its most recent SEC filing.

Amplify Weight Loss Drug & Treatment ETF Price Performance

NYSEARCA THNR opened at $24.41 on Friday. Amplify Weight Loss Drug & Treatment ETF has a 1 year low of $18.56 and a 1 year high of $27.28. The stock has a market capitalization of $3.66 million, a PE ratio of 24.31 and a beta of 0.61. The business’s 50-day moving average is $25.92 and its 200 day moving average is $24.82.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Stockholders of record on Tuesday, December 30th were given a $0.4132 dividend. This represents a dividend yield of 162.0%. The ex-dividend date was Tuesday, December 30th.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.